Home Investigator Content University of California San Diego School of Medicine: Cirmtuzumab Inhibits Stemness of...

University of California San Diego School of Medicine: Cirmtuzumab Inhibits Stemness of Chronic Leukemia Cancer

345
0

Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the “stemness” of chronic leukemia cancer (CLL) cells -; their ability to self-renew and resist terminal differentiation and senescence.

To view article click here

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.